Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.contributor.authorSOUIED, Eric H.
dc.contributor.authorOUBRAHAM, Hassiba
dc.contributor.authorRAZAVI, Sam
dc.contributor.authorMAUGET-FAYSSE, Martine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAVEL, Helene
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHENE, Genevieve
dc.contributor.authorWOLF, Sebastian
dc.date.accessioned2021-04-21T12:09:23Z
dc.date.available2021-04-21T12:09:23Z
dc.date.issued2021-03-01
dc.identifier.issn0275-004xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/27008
dc.description.abstractEnPURPOSE: To assess early changes in spectral-domain optical coherence tomography during the loading phase with intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration. METHODS: In this prospective, open-label, single-arm, multicenter study, patients with neovascular age-related macular degeneration, who were antivascular endothelial growth factor treatment-naïve, received three monthly initial doses of intravitreal aflibercept 2 mg. The primary outcome was the proportion of patients with dry spectral-domain optical coherence tomography at 12 weeks, defined as an absence of intraretinal edema, intraretinal cysts, subretinal fluid, and subretinal pigment epithelium fluid. RESULTS: Fifty eyes of 50 patients were investigated. At 12 weeks, 34.0% (17/50) had dry spectral-domain optical coherence tomography. Marked reductions were observed for all other spectral-domain optical coherence tomography parameters. The mean macular central thickness fell significantly from 463.2 ± 184.3 µm at baseline to 288.9 ± 76.8 µm at Week 12 (P < 0.0001). The mean best-corrected visual acuity also improved significantly from 61.0 ± 16.0 letters at baseline to 66.6 ± 19.0 letters at Week 12 (P = 0.0006). CONCLUSION: The anatomic and functional outcomes improved over the 12-week study period. All outcome variables peaked after the third aflibercept injection, confirming the benefit of three initial doses.
dc.language.isoENen_US
dc.subject.enAflibercept
dc.subject.enCentral retinal thickness
dc.subject.enIntravitreal injection
dc.subject.enIntraretinal edema
dc.subject.enIntraretinal cysts
dc.subject.enNeovascular age-related macular degeneration
dc.subject.enRetinal pigment epithelium
dc.subject.enSpectral-domain optical coherence tomography
dc.subject.enSubretinal fluid
dc.title.enAssessment Of Early Changes In Spectral Domain-Optical Coherence Tomography After Initiation Of Treatment With Intravitreal Aflibercept (Eylea) Over A 12-Week Period For Patients With Neovascular Age-Related Macular Degeneration: A Multicenter French Study (Start)
dc.title.alternativeRetinaen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/iae.0000000000002910en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33600134en_US
bordeaux.journalRETINAen_US
bordeaux.page588-594en_US
bordeaux.volume41en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamUSMRen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03204317
hal.version1
hal.date.transferred2021-04-21T12:09:27Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=RETINA&amp;rft.date=2021-03-01&amp;rft.volume=41&amp;rft.issue=3&amp;rft.spage=588-594&amp;rft.epage=588-594&amp;rft.eissn=0275-004x&amp;rft.issn=0275-004x&amp;rft.au=KOROBELNIK,%20Jean-Francois&amp;SOUIED,%20Eric%20H.&amp;OUBRAHAM,%20Hassiba&amp;RAZAVI,%20Sam&amp;MAUGET-FAYSSE,%20Martine&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée